Firm will immediately make drug available, initially on a named-patient basis.
Deal includes F-star's bispecific antibody targeting LAG-3 and PD-L1; Merck will pay €115 upfront plus R&D funding and milestones, and has option to acquire exclusive development and commercialization rights to the antibodies after F-star delivers predefined data packages
A large Phase III trial, the Impassion130 trial, has produced results supporting the use of chemotherapy plus immunotherapy as first-line treatment in certain patients...
Researchers create GPCR fingerprints that may prove useful in a wide range of therapeutic applications
Belgian women’s health specialist Mithra received orphan drug designation (ODD) from the European Medicines Agency (EMA) for its estrogen candidate, estetrol (E4) as a treatment for neonatal encephalopathy (NE). The firm intends to develop the drug for treating hypoxic ischemic encephalopathy (HIE), and will look for a partner for clinical development.
Expanding on research from the Neurodegeneration Consortium and other entities, Magnolia Neurosciences hopes to develop drugs for peripheral neuropathy and “chemobrain.”
U.S. researchers have used CRISPR/Cas9 screens to identify genes that may protect against or promote the toxicity of protein aggregates in amyotrophic lateral sclerosis (ALS).
Evotec said today it will join Sanofi in partnering with academic institutions to translate their research into new small-molecule drugs across multiple unspecified therapeutic...
Please wait while you are redirected to the right page...